Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) disease and heart failure (HF), and patients with HF frequently die from cancer. Recently, data have been generated showing that circulating factors in relation to HF promote tumour growth and development in murine models, providing proof that a causal relationship exists between both diseases. Several common pathophysiological mechanisms linking HF to cancer exist, and include inflammation, neuro-hormonal activation, oxidative stress and a dysfunctional immune system. These shared mechanisms, in combination with risk factors, in concert may explain why patients with HF are prone to develop cancer. Investigating the new insights linking HF wit...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence de...
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence de...
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence de...
The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of c...
The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of c...
The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of c...
Recent epidemiological analyses suggest that incident cancer may be more common among patients with ...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) d...
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence de...
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence de...
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence de...
The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of c...
The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of c...
The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of c...
Recent epidemiological analyses suggest that incident cancer may be more common among patients with ...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as eac...